Response Genetics, Inc (RGDXQ)

Market Cap	78.00 -99.9%
Revenue (ttm)	16.62M -8.1%
Net Income	-14.21M
EPS	-0.37
Shares Out	38.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,300
Average Volume	7,763
Open	0.0000
Previous Close	0.0000
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.0001
Beta	4.41
RSI	39.36
Earnings Date	n/a

About Response Genetics

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, Respo...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 100
• Stock Exchange: OTCMKTS
• Ticker Symbol: RGDXQ

Financial Performance

In 2014, Response Genetics's revenue was $16.72 million, a decrease of -15.56% compared to the previous year's $19.80 million. Losses were -$13.70 million, 70.8% more than in 2013.